Role of Jawarish Amla as an adjunct to anti-tuberculosis drugs in the symptomatic relief of pulmonary tuberculosis
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20242881Keywords:
Adjuvant, Diqqe revi, DOTS, Jawarish Amla, Pulmonary tuberculosisAbstract
Background: Tuberculosis is a global emergency, with approximately nine million people developing the disease every year. India has the highest TB burden worldwide, accounting for nearly one-fifth of the global burden. DOTS provides an 85% cure rate and symptomatic relief during therapy. However, it has been observed that some troubleshooting symptoms persist during the regimen; therefore, testing and providing a pharmacologically multipotent herbal adjuvant drug can improve compliance with DOTS chemotherapy.
Methods: This study was conducted to explore whether any benefits could be achieved by adding Jawarish Amla to conventional anti-tubercular chemotherapy. Forty patients with pulmonary tuberculosis were enrolled to evaluate the efficacy of Jawarish Amla as adjuvant therapy. Patients were randomly assigned to the control and test groups, with 20 patients in each group. Jawarish Amla was administered to the test group for 60 days along with DOTS and the control group received a placebo with DOTS; for the same duration.
Results: The test drug exhibited statistically significant improvement in almost all parameters, especially appreciated in weight gain (p<0.046), hemoptysis (p<0.0069), breathlessness (p<0.0015), nausea (p<0.001) vomiting (p<0.001), abdominal pain (p<0.001), itching (p<0.001), burning sensation in feet (p<0.001), jaundice (p<0.001), Hb% (p<0.001), ESR (p<0.010), SGOT (p<0.034), SGPT (p<0.020), alkaline phosphatase (p<0.007) and total bilirubin (p=0.069+).
Conclusions: These results indicate that the test drug is safe and effective and especially checks the adverse effects of anti-tubercular drugs used in DOTS therapy. Thus, it can be used as an excellent adjuvant along with DOTS in community management of diqqe revi (pulmonary tuberculosis).
Metrics
References
Herzog H. History of tuberculosis. Respiration. 1998;65:5-15.
Marwan IZ. Kitabut Taisir (Urdu Translation). New Delhi: CCRUM; 1986:234.
Kabeeruddin M. Hummiyate Qanoon (Urdu Translation). Vol. 2. New Delhi: Aijaz Publishing House; 2007:295-315.
Harsh M. Textbook of Pathology. 3rd edn. New Delhi: Jaypee Brothers; 1998: 157-169.
Andreoli TE, Carpenter CCJ, Griggs RC, Benjamin IJ. Cecil Essentials of Medicine. 7th edn. New Delhi: Reed Elsevier; 2008: 250-252.
Hunter AAJ, Colledge RN, Boon AN, Chilvers RE, Christopher H. Davidson’s Principle and Practice of Medicine. 19th edn. New Delhi: Churchill Livingstone; 2004: 157-158, 532-539.
Husain S, Sherwani AM. The prevalence and associated factors for anaemia in school children in Bengaluru, Karnataka, India: a cross-sectional study. Christ J Glob Health. 2023;10(2):22-36.
Husain S, Sherwani AM, Bibi C, Ahmed MW, Raheem A. A cross-sectional study to assess the prevalence and contributing factors of anaemia in private school children in Bengaluru. Int J Community Med Public Health. 2024;11(8):3167.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472-7.
Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu Univ J Sci Engin Tech. 2005;1(1).
Nagayama N, Shishido Y, Masuda K, Baba M, Tamura A, Nagai H, et al. Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid. Kekkaku (Tuberculosis). 2004;79(5):341-8.
Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med. 1992;152(9):1913-9.
Downloads
Published
How to Cite
Issue
Section
